Publications

452 publications

Enter search criteria
Fill in keyword(s) to narrow your search.
Period
You can select a specific type of a publication you are looking for, such as press releases or speeches
Sort by:
  1. Package advice for lock procedure medicinal product darolutamide (Nubeqa®) for the treatment of metastatic prostate cancer

    The National Health Care Institute has assessed whether the medicinal product darolutamide in combination with docetaxel and ...

    Report | 28-07-2023

  2. Package advice eptinezumab (Vyepti®) for the treatment of migraine

    The National Health Care Institute has assessed whether the CGRP inhibitor eptinezumab (Vyepti®) can be reimbursed from the basic ...

    Report | 28-07-2023

  3. Package advice for entrectinib and larotrectinib (Rozlytrek® and Vitrakvi®) for the treatment of adult and paediatric patients with solid tumours (cancer) with NTRK gene fusion

    The National Health Care Institute has assessed whether the medicinal products entrectinib and larotrectinib (Rozlytrek® and ...

    Report | 27-07-2023

  4. GVS advice potassium citrate and potassium hydrogen carbonate (Sibnayal®) for the treatment of distal renal tubular acidosis (dRTA)

    The National Health Care Institute has assessed whether the combination preparation potassium citrate and potassium hydrogen ...

    Report | 19-07-2023

  5. Additional GVS advice nirmatrelvir/ritonavir (Paxlovid®) for the treatment of COVID-19

    The National Health Care Institute assessed whether the reimbursement conditions of the subcutaneous CGRP inhibitors erenumab ...

    Report | 13-07-2023

  6. GVS advice on extension of List 2 reimbursement conditions of subcutaneous CGRP inhibitors

    The National Health Care Institute assessed whether the reimbursement conditions of the subcutaneous CGRP inhibitors erenumab ...

    Report | 11-07-2023

  7. Package advice on the lock procedure medicinal product lenvatinib (Lenvima®) for the treatment of endometrial carcinoma

    The National Health Care Institute has assessed whether the medicinal product darolutamide in combination with docetaxel and ...

    Report | 06-07-2023

  8. GVS advice avacopan (Tavneos®) for the treatment of certain patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)

    The National Health Care Institute has assessed whether avacopan (Tavneos®) can be included in the Medicine Reimbursement System ...

    Report | 15-06-2023

  9. GVS advice hepatitis B vaccine (PreHevbri®) for active immunisation against hepatitis B in adults

    The National Health Care Institute has assessed whether the hepatitis B vaccine PreHevbri® can be included in the Medicine ...

    Report | 02-06-2023

  10. GVS advice lasmiditan (Rayvow®) for the treatment of migraine

    The National Health Care Institute has assessed whether lasmiditan (Rayvow®) can be included in the Medicine Reimbursement System ...

    Report | 23-05-2023